Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis
The American Journal of Tropical Medicine and Hygiene · 2024
DOI: 10.4269/ajtmh.23-0197 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2024. Verfasst von Sutopa Roy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, India. Hauptthemen laut MEDLINE: Leishmaniasis, Visceral, Leishmaniasis, Cutaneous, Leishmania, Leishmania donovani. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.
Abstract (Originalsprache)
Post-kala-azar dermal leishmaniasis (PKDL), the dermal sequel to visceral leishmaniasis (VL), is characterized by hypopigmented macules (macular) and/or papules and nodules (polymorphic). Post-kala-azar dermal leishmaniasis plays a significant role in disease transmission, emphasizing the need for monitoring chemotherapeutic effectiveness. Accordingly, this study aimed to quantify the parasite burden in PKDL patients after treatment with miltefosine by a quantitative polymerase chain reaction (qPCR). A Leishmania kinetoplastid gene-targeted qPCR was undertaken using DNA from skin biopsy specimens of patients with PKDL at three time points, i.e., at disease presentation (week 0, n = 157, group 1), upon completion of treatment (week 12, n = 39, group 2), and at any time point 6 months after completion of treatment (week ≥36, n = 54, group 3). A cycle threshold ( Ct ) 30. The parasite load at disease presentation (group 1) was 10,769 (1,339–80,441)/µg gDNA (median [interquartile range]). In groups 2 and 3, qPCR results were negative in 35/39 cases (89.7%) and 48/54 cases (88.8%), respectively. In the 10/93 (10.8%) qPCR-positive cases, the parasite burdens in groups 2 and 3 were 2,420 (1,205–5,661)/µg gDNA and 22,195 (5,524–100,106)/µg gDNA, respectively. Serial monitoring was undertaken in 45 randomly selected cases that had completed treatment; all cases in groups 2 or 3 had a Ct >30, indicating cure. Overall, qPCR confirmed an 89.2% cure (as 83/93 cases showed parasite clearance), and the persistent qPCR positivity was attributed to nonadherence to treatment or unresponsiveness to miltefosine and remains to be investigated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Institute of Postgraduate Medical Education and Research, Kolkata, India.
- Department of Tropical Medicine, School of Tropical Medicine, Kolkata, India.
- Department of Microbiology, Sarat Chandra Chattopadhyay Government Medical College and Hospital, Howrah, India.
- Kala-Azar Elimination Programme, World Health Organization Country Office, New Delhi, India.
- Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
Förderung
- World Health Organization
Zitieren
APA
Roy, S., Moulik, S., Roy, M., Ghosh, M. K., Chaudhuri, S. J., Pandey, D. K., Jain, S., Dagne, D. A., & Chatterjee, M. (2024). Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.23-0197
Vancouver
Roy S, Moulik S, Roy M, Ghosh MK, Chaudhuri SJ, Pandey DK, et al. Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis. The American Journal of Tropical Medicine and Hygiene. 2024. doi:10.4269/ajtmh.23-0197
BibTeX
@article{Roy2024,
author = {Roy, Sutopa and Moulik, Srija and Roy, Madhurima and Ghosh, Manab K and Chaudhuri, Surya Jyati and Pandey, Dhruv K and Jain, Saurabh and Dagne, Daniel Argaw and Chatterjee, Mitali},
title = {Monitoring the Long-Term Effectiveness of Miltefosine in Indian Post-Kala-Azar Dermal Leishmaniasis},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2024},
doi = {10.4269/ajtmh.23-0197}
}
EUVIMED